SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela PaulsenView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong ZhuView Slideset
MMMala MainiMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Antiviral effect of the RIG-I agonist, Inarigavir | Nezam AfdahlView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPHView Slideset
AGAdam GehringPhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhDView Slideset
TBThomas BergMDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre BoonstraView Slideset
HJHarry JanssenMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What is the cure rate with current therapies? | Harry Janssen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard ColonnoView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew VaillantView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Clinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen YogaratnamView Slideset
